Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For ...

FDA Drug Recall #D-0853-2020 — Class III — February 7, 2020

Recall Summary

Recall Number D-0853-2020
Classification Class III — Low risk
Date Initiated February 7, 2020
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm AuroMedics Pharma LLC
Location East Windsor, NJ
Product Type Drugs
Quantity 4600 Vials

Product Description

Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intravenous Use, Not for Use in Newborns, Contains Benzyl Alcohol, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ, 08520, Made in India, NDC 55150-295-20.

Reason for Recall

Failed Impurities/Degradation Specifications: elevated levels of Benzaldehyde impurity was found in investigative samples (retain samples).

Distribution Pattern

Ohio, Louisiana, Mississippi

Lot / Code Information

Lot #CGP190001-A, Exp. 07/31/2020

Other Recalls from AuroMedics Pharma LLC

Recall # Classification Product Date
D-0020-2023 Class II Fondaparinux Sodium Injection, USP, 7.5 mg per ... Sep 30, 2022
D-0013-2023 Class II Acyclovir Sodium Injection, 500mg/10mL (50mg/mL... Sep 26, 2022
D-1551-2022 Class III Tranexamic Acid Injection, USP, 1000mg per 10 m... Sep 26, 2022
D-0556-2022 Class I Polymyxin B for Injection USP, 500,000 Units pe... Jan 26, 2022
D-0248-2021 Class II Acetaminophen Injection 1,000 mg per 100 mL (10... Dec 30, 2020

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.